Advanced Search

Home > Journals > Minerva Anestesiologica > Past Issues > Minerva Anestesiologica 2013 February;79(2) > Minerva Anestesiologica 2013 February;79(2):185-93



A Journal on Anesthesiology, Resuscitation, Analgesia and Intensive Care

Official Journal of the Italian Society of Anesthesiology, Analgesia, Resuscitation and Intensive Care
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 2,036

Frequency: Monthly

ISSN 0375-9393

Online ISSN 1827-1596


Minerva Anestesiologica 2013 February;79(2):185-93


Rituximab in critically ill patients

Dimopoulos G. 1, Armaganidis A. 1, Poulakou G. 2, Matthaiou D. K. 2

1 Department of Critical Care, Medical School, University of Athens, “Attikon” University Hospital, Athens, Greece;
2 .4th Department of Internal Medicine, Medical School, University of Athens, “Attikon” University Hospital, Athens, Greece

Rituximab is a monoclonal chimeric antibody used in the treatment of CD20-positive B-cell malignancies and rheumatoid arthritis. However, it is used in several other off-label indications including acute graft-versus-host disease. We sought to critically examine the role of rituximab in the treatment of acute graft versus host disease (aGVHD) in critically ill patients and the potential associations with infectious complications in transplant recipients.

language: English


top of page